HL Genomics에이치엘지노믹스

HL Genomics, listed on KOSDAQ in July 2026, has fallen sharply since listing and has no reported revenue or profit figures in the data provided.

HL Genomics shares closed at ₩7,150 on 26 October 2026, near the 52-week low of ₩7,000 and far below the 52-week high of ₩25,550, with a market value of about ₩55.6B. The data shows a price-to-book ratio of 0.6 and cash of about ₩4.9B against borrowings of about ₩0.4B, but no revenue, operating income, net income or annual financial history is included. The company profile is also missing from the data.

What stands out

• Shares are down about 47% over three months and 14.6% over one month, after the July 2026 listing.
• Trailing revenue, operating income, net income and free cash flow are not reported in the data, so profitability cannot be assessed.
• Balance sheet figures shown are cash of about ₩4.9B, borrowings of about ₩0.4B and liabilities-to-equity of 7.6%.
• Foreign ownership rose from 0.1% to 2.4% over about 60 days, while retail and institutional investors were net sellers over the last 20 days.
• Recent filings include a new facility investment report in August 2026 and a shareholder meeting notice in October 2026, but the data does not describe their content.

What to watch

• The half-year report and any detail on revenue and profit, which are absent from the current data.
• The shareholder meeting called in October 2026 and the record date set for it.
• Any news coverage or filing detail on the new facility investment, since no news headlines are currently in the data.